Hormone Resistant Prostate Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate CancerInterventions: Biological: Pembrolizumab; Biological: pTVG-HP Plasmid DNA VaccineSponsors: University of Wisconsin, Madison; National Cancer Institute (NCI)Not yet recruiting - verified July 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2015 Category: Research Source Type: clinical trials
